Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib

Blood Neoplasia · Published 2026-07-01 · DOI 10.1016/j.bneo.2026.100270

Free full text

Authors (14)

Alexander E. Perl, Mark J. Levis, Andrew H. Wei, Hee-Je Kim, June-Won Cheong, Jian Li, Sergey Bondarenko, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Juan Ariza, Jamie Jung-Hee An, Jianxiang Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Perl, A., Levis, M., Wei, A., et al. (2026). Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib. Blood Neoplasia. https://doi.org/10.1016/j.bneo.2026.100270

Related articles

• Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome · Blood Neoplasia · 2026 · Same journal
• Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations · Blood Neoplasia · 2026 · Same journal
• Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report · Blood Neoplasia · 2026 · Same journal
• CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates · Blood Neoplasia · 2026 · Same journal
• Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events · Blood Neoplasia · 2026 · Same journal
• Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report · Blood Neoplasia · 2026 · Same journal
• Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia · Blood Neoplasia · 2026 · Same journal
• Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera · Blood Neoplasia · 2026 · Same journal
• Myeloid cell–mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference · Blood Neoplasia · 2026 · Same journal
• Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study · Blood Neoplasia · 2026 · Same journal